Mustang Bio Announces Final Results From Follicular Lymphoma Cohort Of Single-Institution Phase 1/2 Clinical Trial Of MB-106, CD20-Targeted Autologous CAR T Therapy; 95% Overall Response Rate And 80% Complete Response Rate Across All Patients
Portfolio Pulse from Happy Mohamed
Mustang Bio announced final results from the follicular lymphoma cohort of its Phase 1/2 clinical trial of MB-106, showing a 95% overall response rate and 80% complete response rate across all patients. The company expects to report initial data from its ongoing multicenter trial shortly.
June 15, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mustang Bio's MB-106 Phase 1/2 clinical trial results show promising response rates in follicular lymphoma patients, potentially boosting the company's stock price.
The positive results from Mustang Bio's MB-106 Phase 1/2 clinical trial indicate a high overall response rate and complete response rate in follicular lymphoma patients. This news is likely to be well-received by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100